Intercept pharmaceuticals

Intercept Pharmaceuticals: Building a Healthier Tomorrow for Patients with Progressive Non-Viral Liver Diseases

Intercept Pharmaceuticals is a biopharmaceutical company that is dedicated to developing innovative treatments for patients with progressive non-viral liver diseases. The company was founded in 2002 and has since been at the forefront of research and development in this field.

At Intercept, our mission is to build a healthier tomorrow for patients suffering from liver diseases such as primary biliary cholangitis (PBC), nonalcoholic steatohepatitis (NASH), and other chronic liver diseases. We believe that by focusing on these areas, we can make a significant impact on the lives of millions of people around the world.

Our team consists of some of the most talented scientists, researchers, and medical professionals in the industry. We are committed to advancing our understanding of these complex diseases and developing new treatments that can improve patient outcomes.

One of our most significant achievements to date has been the development of Ocaliva® (obeticholic acid), which was approved by the U.S. Food and Drug Administration (FDA) in 2016 for use in patients with PBC. This breakthrough treatment has been shown to significantly improve liver function tests, reduce serum alkaline phosphatase levels, and alleviate symptoms associated with PBC.

In addition to Ocaliva®, we are also working on several other promising therapies that have shown great potential in clinical trials. These include INT-767, which targets both FXR and TGR5 receptors; INT-777, which targets only TGR5 receptors; and INT-1436, which targets both FXR receptors and bile acid transporters.

At Intercept Pharmaceuticals, we understand that there is still much work to be done when it comes to treating progressive non-viral liver diseases. That's why we are committed to continuing our research efforts until we find effective treatments for all patients who need them.

We also recognize that patient advocacy plays an essential role in achieving our goals. That's why we work closely with patient organizations such as The American Liver Foundation (ALF) and The Global Liver Institute (GLI) to raise awareness about these conditions among healthcare providers, policymakers, and the general public.

In conclusion,

Intercept Pharmaceuticals is a leading biopharmaceutical company dedicated to developing innovative treatments for patients suffering from progressive non-viral liver diseases such as PBC or NASH. Our team consists of some of the most talented scientists who are committed towards advancing their understanding about these complex disorders while developing new therapies aimed at improving patient outcomes.

Our breakthrough treatment Ocaliva® has already received FDA approval while several other promising therapies like INT-767 or INT-777 have shown great potential during clinical trials.

We remain steadfastly committed towards finding effective treatments until every single person suffering from these conditions receives proper care.